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INTRODUCTION
While astrocytomas are a relatively common glial 
neoplasm of the central nervous system, only 3% of the 
cases are found in the spinal cord. The incidence of spinal 
cord astrocytoma is 0.8 to 2.5 out of every 100,000 people 
per year (1). Moreover, systemic metastasis from a spinal 
cord astrocytoma is very rare even when the tumor grade is 
pathologically high (2, 3). The mechanism of extraneural 
metastasis of the tumors of the central nervous system, 
including astrocytoma, is frequently explained as direct 
access of tumor to the extrameningeal tissue via the 
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dural vessels. Lymphatic spread through the invasion of 
the extrameningeal tissue is also possible despite the 
absence of lymphatics in the central nervous system (4). 
In the context of extrameningeal tissue invasion, systemic 
metastasis is reportedly triggered by surgery (4). However, 
there has been no report demonstrating concurrent bony 
metastasis at the time of initial diagnosis of a spinal 
cord astrocytoma. We experienced a case of spinal cord 
astrocytoma with concurrent bone metastasis at the time 
of the initial diagnosis. Although there are reports on 
metastasis of a spinal cord astrocytoma to bone, they 
did not detail the imaging findings (2, 3). Hence, the 
purpose of this article is to present the imaging findings of 
concurrent bone metastasis from a spinal cord astrocytoma 
at the time of the initial diagnosis, and these particular 
imaging findings have never been reported in the English 
medical literature.
CASE REPORT
A 50-year-old male patient was referred to our institution 
for evaluation of a known spinal cord mass. He presented 
with left leg weakness and low back pain for the previous 
6 months. On the lumbar spine magnetic resonance (MR) 
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images taken with a 1.5 Tesla (T) MR scanner and in the 
hospital that referred the patient to us, about a 2 cm sized 
mass that arose from the conus medullaris was found at 
the level of the T12 to L1 vertebrae. Compared with the 
adjacent muscles, the signal intensity of the mass was 
heterogeneously hyperintense on the fat suppressed T2-
weighted image (T2WI) (Fig. 1A) and it was isoinstense on 
the T1-weighted image (T1WI) (Fig. 1B). The mass showed 
multifocal nodular enhancement on the fat-suppressed T1WI 
obtained after the intravenous injection of gadolinium 
contrast agent (Fig. 1C). Although they were overlooked 
during the initial assessment of these MR images from the 
A B C
D
Fig. 1. Bone metastasis identified concurrently with primary spinal cord astrocytoma.
A-C. Fat suppressed T2-weighted image shows heterogeneous hyperintense mass of spinal cord (arrows) at level of T12 and L1 vertebrae (A), 
T1-weighted image shows isointensity of this mass (B), and fat-suppressed contrast enhanced T1-weighted image shows multifocal nodular 
enhancement (C). Fat suppressed T2-weighted image shows heterogeneous hyperintense multiple metastatic bone marrow lesions (arrowheads) 
(A), T1-weighted image shows hypointensity of these lesions (B) and fat suppressed contrast enhanced T1-weighted image shows heterogeneous 
enhancement (C). D. Microscopic examination (Hematoxylin & Eosin staining, original magnification: x 400) reveals high cellularity and nuclear 
pleomorphism (arrows) in fibrillary background without microvessel proliferation or tumor necrosis, which all suggests anaplastic astrocytoma.
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Fig. 1. Bone metastasis identified concurrently with primary spinal cord astrocytoma.
E-H. T2-weighted image shows aggravated multiple bone marrow lesions (arrowheads) with variable signal intensity (E), T1-weighted image 
shows hypointensity of these lesions (F) and contrast enhanced T1-weighted image shows variable contrast enhancement (G). These lesions, 
which correspond to those of MR images, are depicted as osteoblastic lesions on sagittal reformatted CT images of spine (H). I, J. Scintigraphy (I) 
and whole body 18F-FDG PET-CT (J) images of patient. Whole body bone scan (I) shows multiple foci of heterogeneously increased bony uptake 
(arrows) at thoracolumbar spine, rib cage and pelvic bones, which are thought to be consistent with multiple bony lesions seen on CT and MRI. 
Whole body FDG PET image (J) shows increased focal FDG uptake (arrowhead) of vertebral body, which is clearly visualized as being located in 
T11 vertebral body on fusion image of PET-CT. Extraskeletal FDG uptake is not observed.
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referring hospital, multiple bony lesions were present in 
the thoracolumbar vertebral bodies and sacrum. Compared 
with the adjacent muscle, the lesions were heterogeneously 
hyperintense on the fat suppressed T2WI (Fig. 1A) and they 
were hypointense on the T1WI (Fig. 1B). The bony lesions 
showed heterogeneous enhancement on the fat suppressed 
T1WI obtained after the intravenous injection of gadolinium 
compound (CE T1WI) (Fig. 1C). Eight days after the first MR 
imaging, the intramedullary mass was partially removed for 
the purpose of pathologic confirmation and to halt further 
neurologic impairment. The final pathologic examination 
revealed the anaplastic astrocytoma (Fig. 1D). For the 
remaining primary mass, the patient received radiation 
therapy to the spinal canal at the level of the T12 through 
the L1 vertebral bodies with a dosage of 5400 cGy.
The follow-up MR imaging was performed 60 days after the 
surgery to assess the postsurgical and radiotherapy status of 
the spinal cord. The MR images revealed a shrunken primary 
mass of the spinal cord. However, the bony lesions of the 
entire vertebral column were found to be worsened and 
they had become heterogeneous, and bone metastasis was 
considered to have already happened at that time (Fig. 1E-
G). Subsequently, computed tomography (CT) of the chest, 
abdomen and pelvis was performed right after the follow-up 
MR imaging for the further evaluation of distant metastasis. 
Matching all the bony lesions depicted on the MR images 
with those seen on the CT images, the lesions demonstrated 
hyperdense attenuation, suggesting osteoblastic metastasis 
(Fig. 1H). A whole body bone scan and PET-CT (positron 
emission tomography-computed tomography) were also 
sequentially performed within the next two days after the 
CT examinations. On the whole body bone scan images 
obtained from a dual head gamma camera (Millennium 
VG, GE Medical Systems, Milwaukee, WI), multiple foci of 
heterogeneously increased bony uptakes were detected in 
the thoracolumbar spine, the bilateral rib cages and the 
pelvic bones, which were thought to be consistent with 
the multiple bony lesions noted on CT and MRI (Fig. 1I). 
On the whole body 18F-fluorodeoxyglucose (FDG) PET-CT 
using a Biograph 40 (Siemens/CTIMI, Knoxville, TN), among 
all the osteoblastic lesions, focally increased FDG uptake 
was noted only on the T11 vertebral body (the SUV 2.19). 
No extraskeletal metastatic focus was observed on PET-CT 
(Fig. 1J). For an accurate pathologic diagnosis of the bony 
lesions, CT-guided percutaneous biopsy was performed with 
targeting the lesion of the T11 vertebral body based on the 
findings of PET-CT. However, the biopsy revealed a non-
satisfactory result because the amount of specimen was not 
sufficient for making a confirmative diagnosis. Hence, CT-
guided localization was carried out using a guide pin and 
then a subsequent open bone biopsy was done, instead 
of a percutaneous biopsy, for the iliac bone (Fig. 1K). A 
bone block measuring 4 x 1 x 2 cm was obtained, and the 
pathologic result from the specimen revealed metastatic 
anaplastic astrocytoma (Fig. 1L).
The patient had undergone 2 cycles of chemotherapy with 
the use of carboplatin and vincristine before he was found 
to have bone metastasis. However, after the diagnosis of 
K L
Fig. 1. Bone metastasis identified concurrently with primary spinal cord astrocytoma.
K, L. CT-guided localization using guide pin for subsequent open bone biopsy (K) and photomicrograph of surgical specimen from excised bone (L). 
CT image obtained with localization clearly shows guide pin whose tip is located at center of iliac bone, which contains osteoblastic lesions (K). 
Histologic examination of specimen (Hematoxylin & Eosin staining, original magnification × 100) reveals bone marrow and metastatic tumor (T). 
Bone marrow (BM) is infiltrated by metastatic tumor cells (arrowheads) that show histologic findings identical to those of spinal cord tumor.
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bone metastasis, the chemotherapy regimen was changed 
into temozolomide, and cisplatin was also administered to 
the patient during one of the cycles. After the last session 
of chemotherapy, the patient was lost to follow up.
DISCUSSION
Systemic metastasis involving the bone from a spinal 
cord astrocytoma is very rare partly because spinal cord 
astrocytoma is relatively rare per se: spinal cord astrocytoma 
makes up only 3% of all astrocytomas of the central nervous 
system (1). It is also because extraneural metastases from 
central nervous system astrocytomas involving the bone 
are quite rare, and particularly when the spinal cord is the 
primary site (2). Hence, various clinical aspects of systemic 
metastasis from a spinal cord astrocytoma have not been 
well elucidated.
There have been many reports about systemic metastasis 
of astrocytoma, albeit most of the reports have been about 
metastasis from intracranial astrocytomas, which is unlike 
our case. However, with all the reports, there has been 
no report that showed the imaging findings, with using 
various imaging modalities, of bony metastasis from an 
astrocytoma, including the imaging findings of radiography, 
CT, MRI, bone scintigraphy and PET-CT. Among the many 
reports about bony metastasis from astrocytoma with the 
imaging findings and regardless whether the location of 
the primary tumor was intracranial or extracranial, only 
six reports with six cases included the MRI findings of 
metastatic lesions (4-9). The most common MRI finding 
of the bony metastatic lesions from these reports was 
enhancement on the contrast enhanced T1WI, but the signal 
intensity of the lesions on T1WI and T2WI was diverse or 
nonspecific (4-9). These metastatic foci were presented 
as either osteoblastic or osteolytic lesions on the plain 
radiography or CT images. Four cases among them presented 
the scintigraphic findings of the bony metastatic lesions, 
which all showed, except one case, increased bony uptake 
(4, 5, 8, 9). The metastatic lesions of our case also showed 
nonspecific signal intensity and enhancement on the 
gadolinium enhanced T1WI. Particularly, the osteoblastic 
lesions of our case showed heterogeneous signal intensity 
on the T2WI, which is presumed to be associated with 
mineralization of the lesions. In our case, not all the bone 
lesions depicted on MR imaging showed bony uptake on 
scintigraphy, which shows the need of MR imaging for 
assessing bone metastasis even though the metastatic 
lesions were osteoblastic. Regarding the mismatch of the 
findings (the positive MR imaging findings and the negative 
findings on the bone scan at the corresponding locations), 
Taoka et al. (10) explained that early vertebral metastases 
tend to be small and located in the medullary cavity with 
abundant vascularity. They stated that MR imaging is useful 
for the detection of such early intramedullary metastatic 
lesions (10). No previous studies have reported on the PET-
CT findings of metastatic bone tumors from astrocytoma. 
Only the lesion located at the T11 vertebral body in our 
case showed increased FDG uptake, whereas the FDG uptake 
was not strong for the remaining bone marrow lesions. 
We tentatively believe that the routine use of PET-CT, as a 
screening or follow-up tool for bone metastasis, cannot be 
advocated for the case of a spinal cord astrocytoma.
There have been only two old reports about spinal cord 
astrocytomas with accompanying bone metastases (2, 
3). Both the cases were high grade astrocytoma like our 
case. The first report in 1971 was a case of glioblastoma 
multiforme that originated from the lower thoracic spinal 
cord with bone metastases (3). The second report in 1984 
was a case of spinal cord glioblastoma with disseminated 
bone metastases to the ribs, humeri, scapulae, pelvis and 
right femur (2). Our case is the third case of high grade 
spinal cord astrocytoma that metastasized to the bone, but 
it is worthy of notice in two aspects.
Above all, this is the first report where bone metastasis 
from a spinal cord astrocytoma was present at the time 
of the initial diagnosis. In the aforementioned two cases, 
the bony metastases were found after the initial diagnosis. 
Those cases also showed intracranial astrocytomas; 
therefore, it is not completely certain whether the spinal 
cord was the primary focus. As for intracranial astrocytoma, 
concurrent metastasis has been reported just once in 
a case report (4). Additionally, our case demonstrated 
the comprehensive imaging findings, including CT, MRI, 
scintigraphy and PET-CT scans.
To summarize, multiple bony metastases from spinal cord 
astrocytomas are extremely rare, but they are definitely 
within the range of possibility. For patients with high grade 
spinal cord astrocytomas with any subtle abnormality seen 
in the imaging finding of the bones, metastatic bone lesions 
should be scrutinized without hesitation. As for the imaging 
findings, the bony metastatic lesions can be osteolytic or 
osteoblastic on radiographs and CT. On MRI, the lesions 
can be detected earlier as heterogeneous hyperintense 
lesions on T2WI and heterogeneously enhanced lesions on 
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the contrast enhanced T1WI. On scintigraphy and PET-CT 
scanning, the lesions can show variable uptake. If we detect 
bony lesions through any imaging modalities, then we 
should consider a diagnosis of bone metastasis. Pathologic 
confirmation via a bone biopsy may be necessary for a more 
accurate pathologic evaluation.
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